Clinical Trials Browser

Completed × Specimen Handling × Dermatologic × Clear all

NCT06151847 2026-04-30

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT05105100 2026-04-06

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

25 enrolled 13 charts

Melanoma

NCT06861647 2026-04-01

iSITE

Uveal Melanoma

NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Phase EARLY_PHASE1 Completed

Melanoma

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Completed

27 enrolled 16 charts

DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1 Completed

58 enrolled 17 charts

DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT05740501 2023-08-04

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma